SCHEMBL23668175

SCHEMBL23668175

COc1nn(C)cc1Nc1ncc(F)c(-c2cn(S(=O)(=O)c3ccc(C)cc3)c3c(Cl)nccc23)n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ JAK1 P23458 16/20 0.43
▸ JAK2 O60674 12/20 0.43
▸ LRRK2 Q5S007 1/20 0.40
▸ PIM1 P11309 1/20 0.37
▸ PIM2 Q9P1W9 1/20 0.37
▸ JAK3 P52333 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ CCNT1 O60563 1/20 0.36
▸ CCNB2 O95067 1/20 0.36
▸ CCNE2 O96020 1/20 0.36
▸ CDK1 P06493 1/20 0.36
▸ CCNB1 P14635 1/20 0.36
▸ CCNE1 P24864 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ CDK9 P50750 1/20 0.36
▸ CDK5 Q00535 1/20 0.36
▸ CDK5R1 Q15078 1/20 0.36
▸ CCNB3 Q8WWL7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23668192 0.92 JAK1 (0.47) JAK1JAK2LRRK2JAK3KCNH2
SCHEMBL23668178 0.86 FLT3 (0.42) JAK1JAK2JAK3CCNE1CDK2
SCHEMBL30810116 0.84 JAK1 (0.44) JAK1JAK2LRRK2JAK3KCNH2
SCHEMBL23668193 0.82 JAK1 (0.43) JAK1JAK2
SCHEMBL23678830 0.80 JAK1 (0.44) JAK1JAK2LRRK2JAK3KCNH2
SCHEMBL23678817 0.72 JAK1 (0.47) JAK1JAK2LRRK2JAK3KCNH2
SCHEMBL23668182 0.72 ABL1 (0.39) —
SCHEMBL23668179 0.70 LRRK2 (0.52) JAK1JAK2LRRK2JAK3KCNH2
SCHEMBL20399410 0.70 JAK1 (0.44) JAK1JAK2
SCHEMBL30019192 0.70 JAK1 (0.44) JAK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234232-B2 Aromatic heterocyclic compound with kinase inhibitory activity SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2025-02-25 — — US disclosed
US-20210371415-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2021-12-02 — — US disclosed
EP-3854793-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) 2021-07-28 — — EP disclosed
EP-3854793-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) 2021-07-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371415-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY JAK1, JAK2, JAK3 JAK1 1/4885JAK2 2/4885LRRK2 459/4885
US-12234232-B2 Aromatic heterocyclic compound with kinase inhibitory activity JAK1, JAK2, JAK3 JAK1 1/4885JAK2 2/4885LRRK2 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback